{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=meropenem&page=3", "query": { "intervention": "meropenem", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=meropenem&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=meropenem&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T21:30:43.239Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01381562", "title": "GSK2251052 in the Treatment of Complicated Intra-abdominal Infections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Intestinal" ], "interventions": [ { "name": "Drug: GSK2251052", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2011-10-03", "completion_date": "2012-03-05", "has_results": true, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 12, "location_summary": "Mobile, Alabama • Long Beach, California • Torrance, California + 9 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Council Bluffs", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01381562" }, { "nct_id": "NCT00752219", "title": "Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Complicated Intra-abdominal Infections" ], "interventions": [ { "name": "ceftazidime/NXL104 + metronidazole", "type": "DRUG" }, { "name": "meropenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 204, "start_date": "2009-03-31", "completion_date": "2009-12-31", "has_results": true, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 9, "location_summary": "Los Angeles, California • Palm Springs, California • Detroit, Michigan + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Butte", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752219" }, { "nct_id": "NCT04785924", "title": "Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Carbapenem-Resistant Enterobacteriaceae Infection", "KPC", "Gram-Negative Bacterial Infections", "Antibiotic Resistant Infection" ], "interventions": [ { "name": "Imipenem+Relebactam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-06-07", "completion_date": "2023-01-12", "has_results": false, "last_update_posted_date": "2024-09-04", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 1, "location_summary": "Charlotte, North Carolina", "locations": [ { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04785924" }, { "nct_id": "NCT01429259", "title": "Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Cystic Fibrosis", "Pneumonia", "Pseudomonas Aeruginosa Infection" ], "interventions": [ { "name": "meropenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph Kuti", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 30, "start_date": "2012-02", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2018-03-20", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 7, "location_summary": "Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01429259" }, { "nct_id": "NCT02168946", "title": "Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urinary Tract Infection Complicated", "Acute Pyelonephritis", "Hospital Acquired Bacterial Pneumonia", "Ventilator-associated Bacterial Pneumonia", "Bacteremia", "Abdominal Infection" ], "interventions": [ { "name": "Vabomere", "type": "DRUG" }, { "name": "Best Available Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2014-07", "completion_date": "2017-07-21", "has_results": true, "last_update_posted_date": "2019-03-04", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 20, "location_summary": "Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02168946" }, { "nct_id": "NCT04983901", "title": "PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematopoietic and Lymphoid Cell Neoplasm", "Malignant Solid Neoplasm" ], "interventions": [ { "name": "Imipenem/Cilastatin/Relebactam", "type": "DRUG" }, { "name": "Cefepime", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Piperacillin-Tazobactam", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Daptomycin", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2021-09-14", "completion_date": "2023-10-06", "has_results": true, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04983901" }, { "nct_id": "NCT03032380", "title": "Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthcare-associated Pneumonia (HCAP)", "Hospital Acquired Pneumonia (HAP)", "Ventilator Associated Pneumonia (VAP)" ], "interventions": [ { "name": "Cefiderocol", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shionogi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2017-10-24", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2020-11-13", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 15, "location_summary": "New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "DeLand", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Council Bluffs", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03032380" }, { "nct_id": "NCT05102162", "title": "BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Pneumonia" ], "interventions": [ { "name": "Cefepime, Meropenem, or Piperacillin/Tazobactam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 35, "start_date": "2021-12-17", "completion_date": "2023-02-28", "has_results": true, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05102162" }, { "nct_id": "NCT03485950", "title": "Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Other Infectious Diseases" ], "interventions": [ { "name": "Cefepime", "type": "DRUG" }, { "name": "Ceftolozane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Piperacillin-Tazobactam", "type": "DRUG" }, { "name": "Tazobactam", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2018-05-16", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2022-03-15", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03485950" }, { "nct_id": "NCT01499290", "title": "Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complicated Intra-Abdominal Infection" ], "interventions": [ { "name": "CAZ-AVI", "type": "DRUG" }, { "name": "Metronidazole", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 493, "start_date": "2012-03", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-09-06", "last_synced_at": "2026-10-20T21:30:43.239Z", "location_count": 4, "location_summary": "Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Somers Point", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499290" } ] }